FiercePharma

BRILINTA (ticagrelor) Tablets Now Available in U.S. Pharmacies for Patients with Acute Coronary Syndrome

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that BRILINTA TM (ticagrelor) tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.
TCTMD

Health Canada approves BRILINTA (ticagrelor tablets)

AstraZeneca today announced that Health Canada has approved BRILINTA (ticagrelor tablets) for the secondary prevention of atherothrombotic events in patients with Acute Coronary Syndromes (ACS). It is ...
Business Wire

BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

When possible, interrupt therapy with BRILINTA for 5 days prior to surgery that has a major risk of bleeding. If BRILINTA must be temporarily discontinued, restart as soon as possible Ticagrelor can ...
FierceBiotech

New ESC Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients with ST-Elevation

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised “Guidelines on the Management ...
TCTMD

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

BRILINTA indicated to reduce heart attacks and cardiovascular death in patients with Acute Coronary Syndrome WILMINGTON, Del. - AstraZeneca announced today that the US Food and Drug Administration ...
Fierce Healthcare

AstraZeneca Announces Increased Coverage of BRILINTA (Ticagrelor) Through Plan Preferred Formulary Status on Medco Health

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced that BRILINTA ® (ticagrelor) tablets received Plan Preferred Tier 2 formulary access on Medco Health Solutions’ National ...
MedPage Today

With Ticagrelor, Aspirin May Not Be Needed After PCI for Acute Coronary Syndrome

ATLANTA -- In select patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes who were event-free for 1 month on dual antiplatelet therapy (DAPT), treatment with ...
Monthly Prescribing Reference

Ticagrelor Under Review for Reduction of Subsequent Stroke in High-Risk Patients

Credit: Getty Images. The FDA has granted Priority Review of the supplemental New Drug Application for Brilinta (ticagrelor; AstraZeneca), for use in combination with aspirin, to reduce the rate of ...
FierceBiotech

Results from Two Phase II Trials Add to Understanding of Brilinta (Ticagrelor) and How it Works in the Body

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, ...
Fierce Healthcare

BRILINTA (ticagrelor) Launches “Complete the Course” — a Creative Education Program for Patients With ACS, Including “Access My BRILINTA” Support Service Focused on ...

(NYSE: AZN) today introduced a creative education program to support patients taking BRILINTA(ticagrelor). Patients who enroll in the program receive support services across multiple channels to help ...
Healio

Ticagrelor for ACS confers similar net events but more bleeding, dyspnea vs. clopidogrel

Please provide your email address to receive an email when new articles are posted on . For patients with ACS, ticagrelor after PCI demonstrated similar rates of net adverse clinical events at 1 year ...